Lehmann Roger, Weber Markus, Berthold Peter, Züllig Richard, Pfammatter Thomas, Moritz Wolfgang, Mädler Kathrin, Donath Marc, Ambühl Patrice, Demartines Nicolas, Clavien And Pierr-Alain, Andreia Spinas Giatgen
Departments of Radiology and Visceral Surgery, University Hospital, CH-8091 Zurich, Switzerland.
Am J Transplant. 2004 Jul;4(7):1117-23. doi: 10.1111/j.1600-6143.2004.00468.x.
We report on the feasibility of a glucocorticoid-free immunosuppression (sirolimus, low-dose tacrolimus, and daclizumab) in simultaneous islet-kidney transplantation in nine patients with type 1 diabetes. There was one renal primary nonfunction. Renal function (n = 8) as assessed by creatinine and creatinine clearance over time was 103 +/- 6 micromol/L and 64 +/- 6 mL/min/1.73 m(2), respectively. Five out of six patients with >or= 2 islet transplantations became insulin independent. The mean HbA(1c) during the follow-up period for all patients after transplantation is 6.2 +/- 0.9% as compared with 8.7 +/- 1.9% prior to transplant. These results in patients with a median follow-up of 2.3 years suggest that kidney transplantation under a glucocorticoid-free immunosuppression is feasible, and that the rate of insulin independence of 80% can be achieved not only in patients with no or minimal diabetes complications, but also in patients with more advanced late complications and in conjunction with kidney transplantation.
我们报告了在9例1型糖尿病患者同时进行胰岛-肾脏移植时采用无糖皮质激素免疫抑制方案(西罗莫司、低剂量他克莫司和达利珠单抗)的可行性。有1例出现原发性肾功能无功能。随着时间推移,通过肌酐和肌酐清除率评估的肾功能(n = 8)分别为103±6微摩尔/升和64±6毫升/分钟/1.73平方米。6例接受≥2次胰岛移植的患者中有5例不再依赖胰岛素。所有患者移植后随访期间的平均糖化血红蛋白为6.2±0.9%,而移植前为8.7±1.9%。对中位随访时间为2.3年的患者的这些结果表明,无糖皮质激素免疫抑制下的肾脏移植是可行的,不仅在无糖尿病并发症或并发症极少的患者中,而且在有更晚期并发症的患者中以及与肾脏移植联合进行时,均可实现80%的胰岛素非依赖率。